Genzyme Ireland Limited — FDA Warning Letter, 2026-06-22: CGMP/Deviations/Biologics License Application (BLA)
Letter issued · posted to fda.gov .
Subject as published: CGMP/Deviations/Biologics License Application (BLA)
TL;DR
The FDA Center for Biologics Evaluation and Research (CBER) issued a warning letter to Genzyme Ireland Limited on June 22, 2026 (CBER 26-728681), following an inspection conducted January 12-20, 2026, documenting significant current good manufacturing practice (CGMP) violations in the manufacture of Thymoglobulin and Altuviiio. The violations include failure of the quality control unit to ensure laboratory records contained complete test data, exercise proper oversight of environmental monitoring documentation, and thoroughly investigate deviations and batch failures—resulting in products that are adulterated under 21 U.S.C. § 351(a)(2)(B). The FDA determined that the firm's responses to inspectional observations addressed individual deficiencies but failed to identify and correct the systemic failure of the quality unit's CGMP oversight responsibilities.
Argus analysis
# FDA Warning Letter Analysis: Genzyme Ireland Limited
**Company and Findings**
Genzyme Ireland Limited, a Sanofi subsidiary located in County Waterford, received a warning letter from the FDA's Center for Biologics Evaluation and Research (CBER) on June 22, 2026, following a January 2026 facility inspection. The inspection documented significant current good manufacturing practice (CGMP) violations in the manufacture of two licensed biological products: Thymoglobulin (Anti-thymocyte Globulin [Rabbit]) and Altuviiio (antihemophilic factor [recombinant]). The FDA determined that manufacturing methods, facilities, and controls did not conform to CGMP standards, rendering the products adulterated and their introduction into interstate commerce a prohibited act.
**Regulatory Citations and Context**
The violations centered on quality control unit oversight under 21 CFR 211.22, with specific failures cited under 21 CFR 211.194(a) and 21 CFR 211.192. These sections require complete laboratory records documenting all necessary tests and thorough investigation of unexplained discrepancies or specification failures. Genzyme's violations included undocumented particulate excursions, incomplete environmental monitoring records, use of uncontrolled review checklists that were subsequently discarded, and cancellation of numerous deviations without root cause investigation or product impact assessment.
**Response Timeline and Industry Watch Points**
Genzyme had 15 working days from letter receipt to submit a written response. The FDA rejected the company's initial responses (February through April 2026) as addressing individual observations without addressing systemic quality unit failures. Compliance officers should monitor whether Genzyme provides: a comprehensive data integrity assessment across all operations, expanded retrospective deviation reviews beyond the initially selected timeframe, and revised investigation documentation resolving discrepancies in deviation records. The letter warns that failure to adequately address matters may result in seizure and injunction without further notice.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Genzyme Ireland Limited MARCS-CMS 728681 — June 22, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via UPS and EMAIL Reference #: CBER 26-728681 Product: Biologics Recipient: Recipient Name Mr. Cian O'Brien Recipient Title Site Head Genzyme Ireland Limited Unit 701 IDA Industrial Park Old Kilmeaden Road Co. Waterford X91 TP27 Ireland Cian.OBrien@sanofi.com Issuing Office: Center for Biologics Evaluation and Research (CBER) United States WARNING LETTER June 22, 2026 CBER 26-728681 Dear Mr. O'Brien: The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between January 12, 2026, and January 20, 2026. During the inspection, FDA documented evidence of significant violations of current good manufacturing practice (CGMP) requirements, see 21 U.S.C. § 351(a)(2)(B) and 21 CFR parts 210 and 211, in the manufacture of your licensed biological products, Thymoglobulin (Anti-thymocyte Globulin [Rabbit]) and Altuviiio (antihemophilic factor [recombinant]) (collectively, “your products”). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 351(a)(2)(B). Your introduction of your products into interstate commerce is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a). FDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). The CGMP violations applicable to your products include, but are not limited to, the following: 1. Your firm’s quality control unit failed to exercise its responsibility to ensure that drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity, as required by 21 CFR 211.22. Specifically, your quality unit failed to exercise its responsibility to ensure compliance with the following CGMP requirements: a. Failure to ensure that laboratory records include complete data derived from all tests necessary to assure compliance with established specifications and standards, as required by 21 CFR 211.194(a). For example: i. Multiple non-viable particulate excursions and repeated (b)(4) test failures across multiple batches present in instrument histories were not documented in laboratory records for review and investigation. (b)(4) testing was repeated up to 11 times without documentation. ii. On multiple occasions, the number of active air monitoring samples documented in environmental monitoring records was not directly traceable to the instrument histories of the specific air samplers identified on those records. Additionally, logbooks documenting when environmental monito…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was Genzyme Ireland Limited cited for?
- The FDA Warning Letter to Genzyme Ireland Limited (issuing office: Center for Biologics Evaluation and Research (CBER)) cites: CGMP/Deviations/Biologics License Application (BLA). Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Genzyme Ireland Limited?
- FDA issued the letter (MARCS-CMS 728681) on 2026-06-22 and posted it publicly on fda.gov on 2026-06-30.
- Is the FDA warning letter to Genzyme Ireland Limited publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genzyme-ireland-limited-728681-06222026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Genzyme Ireland Limited — FDA Warning Letter, 2026-06-22: CGMP/Deviations/Biologics License Application (BLA). Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-genzyme-ireland-limited-2026-06-22-cgmp
"Genzyme Ireland Limited — FDA Warning Letter, 2026-06-22: CGMP/Deviations/Biologics License Application (BLA)." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-genzyme-ireland-limited-2026-06-22-cgmp.
Argus HQ Research. "Genzyme Ireland Limited — FDA Warning Letter, 2026-06-22: CGMP/Deviations/Biologics License Application (BLA)." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-genzyme-ireland-limited-2026-06-22-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_genzyme_ireland_limited_2026_06_22_cgmp_2026,
title = {Genzyme Ireland Limited — FDA Warning Letter, 2026-06-22: CGMP/Deviations/Biologics License Application (BLA)},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-genzyme-ireland-limited-2026-06-22-cgmp},
note = {Accessed: July 13, 2026}
}